Nachhaltige Energieversorgung und Integration von Speichern

Abstract

The purpose of this study was to determine the occurrence and clinical value of anti-cardiolipin antibodies inpatients with Sjogren's syndrome. Thirty one patients with primary Sjogren's syndrome (all women, mean (SD) age 48-3 (11-2) years) and 32 patients with secondary Sjogren's syndrome with rheuma-toid arthritis (all women, mean (SD) age 54 9 (11) years) were studied. IgG, IgM, and IgA anticardiolipin antibodies were determined by a standard enzyme linked immunosorbent assay (ELISA) technique. Anticardiolipin antibodies were found in five patients (16%) with primary Sjogren's syndrome and in seven patients (22%) with secondary Sjogren's syn-drome. There was no correlation between anticardiolipin antibodies and the clinical features of the antiphospholipid syndrome (thrombotic events, fetal loss, thrombocyto-penia) or extraglandular manifestations of Sjogren's syndrome (arthritis, skin lesions, myositis, polyneuropathy, central nervous system disease, pulmonary and renal disease) in either group. Among the various serological features studied, anticardiolipin antibodies correlated with antinuclear antibodies and antibodies to RNP only in patients with primary Sjogren's syndrome. These results indicate that although anticardiolipin anti-bodies are often found in serum samples from patients with Sjogren's syndrome, their clinical significance remains unclear.